Vir Biotechnology (VIR) EBITDA Margin Growth (3y) (2021 - 2026)
Powered by 
Analysis
Vir Biotechnology (VIR) EBITDA Margin Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | -377.00 |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | -204.00 |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 7,045.00 |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -1,934.00 |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 7,261.00 |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 9,003.00 |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | -2,649.00 |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 30,461.00 |
| 10 | Vir Biotechnology | 1.92 Bn | 1.92 Bn | 238.95 Mn | 569,801.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 569,801.00 |
| Mar 31, 2026 | -45.59 Mn |
| Dec 31, 2025 | 22,980.00 |
| Sep 30, 2025 | -7.23 Mn |
| Jun 30, 2025 | -919,995.00 |
| Mar 31, 2025 | -468,473.00 |
| Dec 31, 2024 | -101,709.00 |
| Sep 30, 2024 | -966,713.00 |
| Jun 30, 2024 | -519,316.00 |
| Mar 31, 2024 | 788,594.00 |
| Dec 31, 2023 | 542,356.00 |
| Sep 30, 2023 | -253,152.00 |
| Jun 30, 2023 | -562,390.00 |
| Mar 31, 2023 | 102,988.00 |
| Dec 31, 2022 | 620,142.00 |
| Sep 30, 2022 | 345,048.00 |
| Jun 30, 2022 | 119,305.00 |
| Mar 31, 2022 | 92,274.00 |
| Dec 31, 2021 | 92,755.00 |
| Sep 30, 2021 | 113,898.00 |